Clinical trial
MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation…
NCT00452491 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00452491 |
|---|---|
| Title | MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children |
| Official title | A Cohort of Pre-pubertal Children for the Study of Optimization of Methods of Administration of the Biosynthetic Growth Hormone MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fetal Growth Retardation |
| Intervention type | Drug |
| Interventions | somatropin |
| Enrollment | 306 |
| Start date | May 1, 1993 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Mar 27, 2007 |
| Last update posted | Oct 5, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: